Related Experiment Video

Updated: Sep 29, 2026

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats
04:38

A Middle Cerebral Artery Occlusion Technique for Inducing Post-stroke Depression in Rats

Published on: May 22, 2019

Effect of cerebrovascular risk factors on depression treatment outcome in later life

Mark D Miller1, Eric J Lenze, Mary Amanda Dew

  • 1Intervention Research Center in Late-Life Mood Disorders, Department of Psychiatry, University of Pittsburgh School of Medicine, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. millermd@msx.upmc.edu

The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry
|September 6, 2002
PubMed

Insights

High cerebrovascular risk factors (CVRF) in late-life depression do not negatively impact treatment outcomes or predict specific clinical features. This suggests optimism for treating late-life depression, regardless of vascular risk.

Area of Science:

  • Geriatric Psychiatry
  • Neuroscience
  • Cardiovascular Health

Background:

  • The vascular depression hypothesis suggests late-life depression stems from cerebrovascular damage, leading to distinct, chronic, and treatment-resistant presentations.
  • Understanding the influence of cerebrovascular risk factors (CVRF) on late-life depression is crucial for effective treatment strategies.

Purpose of the Study:

  • To investigate the relationship between CVRF and the clinical presentation of late-life recurrent major depression.
  • To assess the impact of CVRF on treatment outcomes, including time to remission and recurrence risk, in a long-term maintenance study.

Main Methods:

  • 156 subjects with late-life recurrent major depression were enrolled in a long-term maintenance treatment study.
  • Cerebrovascular risk factor (CVRF) scores were calculated using the Probability of Stroke Risk Profile.
  • Subjects were categorized into High CVRF and non-High CVRF groups for comparative analysis of clinical presentation and treatment outcomes.

Main Results:

  • A higher proportion of subjects in the High CVRF group experienced first-onset depression after age 60.
  • High CVRF score, late onset of depression, or their interaction did not affect time to remission, need for adjunctive medication, or recurrence risk over 3 years.
  • High CVRF and late onset depression did not predict characteristic clinical features of vascular depression, such as psychomotor retardation or lack of insight.

Conclusions:

  • The presence of high cerebrovascular risk does not appear to diminish the prognosis for late-life depression treatment outcomes.
  • Clinicians can maintain optimism regarding treatment efficacy for late-life depression, even in the presence of significant vascular risk factors.
Abstract

Related Concept Videos

Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
Depression: Overview01:18

Depression: Overview

Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...